Your browser doesn't support javascript.
loading
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
Kimmich, Christoph R; Terzer, Tobias; Benner, Axel; Hansen, Timon; Carpinteiro, Alexander; Dittrich, Tobias; Veelken, Kaya; Jauch, Anna; Huhn, Stefanie; Basset, Marco; Goldschmidt, Hartmut; Müller-Tidow, Carsten; Schönland, Stefan O; Hegenbart, Ute.
Afiliación
  • Kimmich CR; Division of Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Terzer T; Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.
  • Benner A; Department of Oncology and Hematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany.
  • Hansen T; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Carpinteiro A; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Dittrich T; Hematology/Oncology practice, Hämatologisch-Onkologische Praxis Altona, Hamburg, Germany.
  • Veelken K; Department of Hematology, University Hospital Essen, Essen, Germany.
  • Jauch A; Division of Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Huhn S; Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.
  • Basset M; Division of Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Goldschmidt H; Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.
  • Müller-Tidow C; Institute of Human Genetics, University Heidelberg, Heidelberg, Germany.
  • Schönland SO; Division of Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Hegenbart U; Division of Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Am J Hematol ; 96(7): E253-E257, 2021 07 01.
Article en En | MEDLINE | ID: mdl-33844864
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cromosomas Humanos Par 1 / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas / Lenalidomida / Anticuerpos Monoclonales Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2021 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cromosomas Humanos Par 1 / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas / Lenalidomida / Anticuerpos Monoclonales Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2021 Tipo del documento: Article País de afiliación: Alemania